# Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023

## TL;DR

This study reports on the antimicrobial resistance of Candida auris in the U.S. from 2022–2023, highlighting the need for improved lab testing to combat this public health threat.

## Contribution

The study provides updated resistance data for C. auris and emphasizes the importance of laboratory capacity for identification and susceptibility testing.

## Key findings

- 95% of C. auris isolates were resistant to fluconazole.
- 15% showed resistance to amphotericin B and 1% to echinocandins.
- The study underscores the need for enhanced laboratory capabilities to address C. auris.

## Abstract

During 2022–2023, the Antimicrobial Resistance Laboratory Network tested 8,033 Candida auris clinical isolates in the United States. Overall, 95% of isolates were fluconazole resistant, 15% amphotericin B resistant, and 1% echinocandin resistant. Laboratory capacity for C. auris identification and antifungal susceptibility testing is essential to address this emerging public health threat.